Feb 02, 2021
Sirnaomics to Present at Medical Dermatology Summit
Jan 17, 2021
Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
Oct 22, 2020
Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections
Aug 25, 2020
Sirnaomics Publishes Preclinical Study of Novel siRNA-Gemcitabine Conjugate for Advancing RNAi Therapeutics to Treat Multiple Types of Cancers
Jun 11, 2020
Sirnaomics Announces Decision to Spin off RNAimmune to Develop Novel mRNA Therapeutics and Vaccines
Apr 08, 2020
Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC)
Mar 09, 2020
Sirnaomics to Showcase Data for Lead Product STP705 in Human Squamous Carcinoma Tumor Model at 2020 American Academy of Dermatology Annual Meeting
Feb 10, 2020
Sirnaomics' siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma
Jan 24, 2020
Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV
Jan 07, 2020
Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining STP705 and Sintilimab in the US
Jan 07, 2020
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US
Nov 06, 2019
Sirnaomics to Present Overview of Company's RNAi Technology Platform at Upcoming Conferences
Oct 31, 2019
Sirnaomics to Present Preclinical STP705 Data Suggesting Reduction in Liver Fibrosis at AASLD Liver Meeting
Oct 24, 2019
Sirnaomics Leadership to Speak at 7th China Renaissance Healthcare and Life Sciences Summit
Oct 09, 2019
Sirnaomics' President and CEO Patrick Lu to Give Keynote Address at RNAi China Conference
May 28, 2019
Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer
May 16, 2019
Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract
Apr 26, 2019
Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics for Treatment of Cancer and Fibrotic Diseases
Mar 11, 2019
Sirnaomics to Present at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery
Feb 25, 2019
Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Liver Cancer Animal Model at AsiaTIDES